VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-14 · 9 min read

Vetmedin for Dogs: Stage B2 MVD, CHF, and Why Echo Timing Matters

Vetmedin (pimobendan) for dogs — FDA-approved to delay CHF in Stage B2 MMVD and to treat congestive heart failure. Staging, echo criteria, dosing, and monitoring.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Vetmedin (pimobendan) is the only medication FDA-approved to delay the onset of congestive heart failure (CHF) in dogs with preclinical myxomatous mitral valve disease (MMVD). As of December 2025, that approval is no longer conditional — the FDA granted full approval for the Stage B2 indication based on two multi-site studies, including the EPIC trial. Pimobendan is also approved for the management of clinical CHF due to MMVD or dilated cardiomyopathy (DCM).

But pimobendan is not a drug for every dog with a heart murmur. The staging criteria are specific, the dosing schedule is unforgiving, and starting it at the wrong stage can expose a dog to medication without evidence of benefit. This article explains what pimobendan does, when it is indicated, how staging works, and what monitoring it requires.

Quick answer

Pimobendan is an inodilator — it increases the strength of cardiac contraction (positive inotrope) through calcium sensitization, and dilates blood vessels (vasodilator) through phosphodiesterase III (PDE3) inhibition. It is dosed at 0.25–0.3 mg/kg orally every 12 hours and must be given on an empty stomach (1 hour before food). Giving it with food reduces bioavailability by approximately 30%.

In dogs with Stage B2 MMVD (asymptomatic but with cardiomegaly), the EPIC trial showed pimobendan delayed onset of CHF by approximately 15 months. In dogs already in CHF (Stage C), it is a cornerstone of therapy alongside furosemide and an ACE inhibitor.

Why the Stage B2 approval matters

Myxomatous mitral valve disease is the most common acquired heart disease in dogs, accounting for approximately 70–75% of all canine heart disease. It is particularly prevalent in small and medium breeds — Cavalier King Charles Spaniels, Miniature Poodles, Dachshunds, Chihuahuas, Cocker Spaniels, Shih Tzus, Maltese, and others. Roughly 10% of all dogs will be diagnosed with heart disease in their lifetime.

Most dogs with MMVD never progress to heart failure. They live their entire lives with a murmur that never causes clinical signs. But a subset — those whose hearts enlarge as the valve degenerates — are at high risk for progression to CHF. Identifying those dogs and starting treatment at the right moment is the clinical challenge.

The FDA first conditionally approved Vetmedin for the Stage B2 preclinical indication in 2022 under its expanded conditional approval authority. After three annual renewals and the submission of effectiveness data, full approval was granted on December 19, 2025 — the first time the FDA has granted full approval of an animal drug indication that was initially conditionally approved under this pathway.

ACVIM staging and when pimobendan fits

The American College of Veterinary Internal Medicine (ACVIM) consensus guidelines classify MMVD into stages. The staging determines whether pimobendan is indicated.

Stage Definition Pimobendan indicated?
A At risk (breed predisposition, no murmur) No
B1 Murmur present, no cardiomegaly No
B2 Murmur present with cardiomegaly, no clinical signs Yes — to delay CHF onset
C Current or past CHF due to MMVD Yes — as part of CHF management
D Refractory CHF despite standard therapy Yes — dose escalation common

Stage B1 and B2 are both asymptomatic. The difference is cardiac enlargement. That distinction requires imaging — a chest X-ray and echocardiogram. You cannot differentiate B1 from B2 on auscultation alone.

The EPIC study evidence

The EPIC trial (Evaluation of Pimobendan in Dogs with Cardiomegaly) was a randomized, double-blind, placebo-controlled study that enrolled 360 dogs across 11 countries.

Inclusion criteria

  • Age 6 years or older
  • Body weight 4.1–15 kg
  • MMVD murmur grade 3/6 or higher
  • Radiographic evidence of cardiomegaly (vertebral heart score >10.5)
  • Echocardiographic evidence of cardiomegaly: LA/Ao ratio ≥1.6 and normalized left ventricular internal diameter in diastole (LVIDdN) ≥1.7

Key results

  • Median time to primary endpoint (CHF or cardiac-related death): 1,228 days (Vetmedin) vs. 766 days (placebo) — a difference of approximately 15 months (the FDA announcement references 14.2 months based on a separate analysis).
  • The study was stopped early because the benefit was so clear.
  • No increase in adverse events compared to placebo.
  • Echocardiographic follow-up showed reverse remodeling — decreased left ventricular and left atrial size — suggesting a structural mechanism for the clinical benefit.

A second study used a historical control group from EPIC and found that 79.2% of Vetmedin-treated dogs were successfully managed for one year without developing CHF.

The echo timing problem

The hardest part of starting pimobendan in Stage B2 is not the prescription — it is confirming that the dog is actually in Stage B2. A dog needs all three criteria met:

  1. A murmur grade ≥3/6 on auscultation
  2. Radiographic cardiomegaly (VHS >10.5)
  3. Echocardiographic cardiomegaly (LA/Ao ≥1.6 AND LVIDdN ≥1.7)

A murmur alone is not enough. A murmur with an enlarged heart on X-ray but normal echo measurements is not enough. Both echocardiographic criteria must be met — this is the threshold at which the EPIC trial demonstrated benefit.

This means that a veterinarian who suspects Stage B2 needs to refer for or perform an echocardiogram. Starting pimobendan in a dog with a loud murmur but no cardiomegaly (Stage B1) is not supported by evidence. The ACVIM guidelines explicitly state that Stage B1 dogs do not benefit from pimobendan.

For Cavalier King Charles Spaniels and other high-risk breeds, many cardiologists recommend screening echocardiograms starting around middle age, even before the murmur becomes loud, to establish baseline measurements and track progression.

Dosing and the empty-stom problem

The label dose is 0.25–0.3 mg/kg orally every 12 hours. Vetmedin is available as chewable tablets (1.25 mg, 2.5 mg, 5 mg, and 10 mg) and as an oral solution.

The administration constraint that owners most often get wrong: pimobendan must be given on an empty stomach, ideally 1 hour before feeding. Giving it with a meal reduces oral bioavailability by roughly 30%. In a progressive disease where drug levels matter, this is clinically significant.

The practical implication is rigid scheduling. If the first dose is at 7:00 AM and food follows at 8:00 AM, the second dose is at 7:00 PM with dinner at 8:00 PM. That schedule works for early risers but is harder for households where no one is home mid-morning. The alternative is to make the morning meal the main meal and feed dinner later in the evening.

If a dose is missed, give it as soon as possible. If it is almost time for the next dose, skip the missed dose. Do not double-dose.

Stage C and D: pimobendan in heart failure

Once a dog develops CHF (Stage C), pimobendan remains part of the standard therapy, but it is no longer used alone. The ACVIM consensus recommends:

  • Furosemide — loop diuretic to clear pulmonary edema. Starting dose typically 1–2 mg/kg IV/IM/SC during acute crisis, then 2 mg/kg PO q12h for maintenance.
  • Pimobendan — 0.25–0.3 mg/kg PO q12h, continued.
  • ACE inhibitor (enalapril or benazepril) — 0.5 mg/kg PO q12h. Added once the acute crisis is managed.
  • Spironolactone — aldosterone antagonist, added in some protocols.

For Stage D (refractory CHF), options include dose escalation of pimobendan to 0.4–0.5 mg/kg PO q8h (extra-label), substitution of furosemide with torsemide, and additional diuretics.

Side effects

From the controlled field studies:

  • Poor appetite (38% in the CHF field study)
  • Lethargy (33%)
  • Diarrhea (30%)
  • Dyspnea (29%)
  • Azotemia (14%)
  • Weakness and ataxia (13%)

These rates are from dogs already in CHF, where the underlying disease contributes to many of these signs. In the EPIC trial (preclinical dogs), adverse events were not significantly different from placebo.

Contraindications: do not use in dogs with hypertrophic cardiomyopathy, aortic stenosis, or any condition where augmentation of cardiac output is functionally or anatomically inappropriate.

Precautions: safety has not been established in dogs younger than 6 months, dogs with congenital heart defects, dogs with diabetes mellitus or serious metabolic diseases, or dogs used for breeding, or pregnant or lactating bitches.

What monitoring looks like

Stage Monitoring
B2 (preclinical) Recheck echocardiogram every 6–12 months to track LA/Ao and LVIDdN. Monitor resting respiratory rate at home (goal <30 breaths per minute at rest). Annual bloodwork.
C (CHF) Recheck 7–14 days after starting or adjusting furosemide dose. Renal values, electrolytes. Thoracic radiographs to confirm edema resolution. Recheck echocardiogram as clinically indicated.
D (refractory) More frequent rechecks. Renal values and electrolytes with each diuretic adjustment. Serial thoracic radiographs.

Home respiratory rate monitoring is one of the most practical tools for owners. A sustained rise above 30 breaths per minute at rest in a dog previously diagnosed with MMVD warrants a veterinary visit — it may indicate developing pulmonary edema.

Practical decisions: what to ask your veterinarian

  • What stage is my dog in? If the answer is "a murmur, but we haven't done an echo," the staging is incomplete. An echocardiogram is needed to determine whether pimobendan is indicated.
  • Does my dog meet the EPIC criteria? Specifically: is the LA/Ao ≥1.6 and LVIDdN ≥1.7? Both must be met, not just one.
  • How do I manage the empty-stomach dosing? This is the practical barrier for most owners. Work out a schedule that fits your household before leaving the clinic.
  • What respiratory rate should worry me? Get a specific number (usually 30 breaths per minute at rest) and a plan for what to do if it rises.

Sources

Topics
Cardiology
Related Articles